An alpha-melanocyte-stimulating-hormone analogue examined in an early pigmentation study.
Melanotan 2, also called Melanotan II, is a synthetic analogue of a pigment-related hormone signal. The selected early human study examined pigmentation; a small trial does not establish safety for cosmetic use.
Melanotan-II is not the same compound as every other melanocortin analogue. A small early trial is not proof of cosmetic-use safety.
Reviewed 2026-10-26
Human — small pilot trial
3 male volunteers.
The alpha-MSH analogue was studied for pigmentation; two participants had increased pigmentation after the study.
Nausea, fatigue/somnolence and spontaneous prolonged erections occurred. Three volunteers cannot establish cosmetic-use safety or long-term risk.
PMID 8637402. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Compound name and formula checked via PubChem PUG REST. This reference does not verify the vial, salt or formulation.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Melanotan 2, also called Melanotan II, is a synthetic analogue of a pigment-related hormone signal. The selected early human study examined pigmentation; a small trial does not establish safety for cosmetic use.
The Melanotan 2 profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Melanotan-II: pilot phase 1 study (1996): Human — small pilot trial
Publication: Melanotan-II: pilot phase 1 studyMelanotan-II: pilot phase 1 study (1996): 3 male volunteers.
Publication: Melanotan-II: pilot phase 1 studyMelanotan-II is not the same compound as every other melanocortin analogue. A small early trial is not proof of cosmetic-use safety.
Melanotan-II: pilot phase 1 study (1996): Nausea, fatigue/somnolence and spontaneous prolonged erections occurred. Three volunteers cannot establish cosmetic-use safety or long-term risk.
Publication: Melanotan-II: pilot phase 1 studyThese studies do not establish the identity, purity, safety or effects of the MXC Melanotan 2 vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.